Breaking News: Drug Prices Soar Despite Trump’s Promises—Here’s What You Need to Know
In a move that’s sure to spark outrage, drugmakers are set to raise prices on over 350 medications in the U.S., including critical vaccines for COVID, RSV, and shingles, as well as the blockbuster cancer treatment Ibrance. But here’s where it gets controversial: these hikes are happening despite intense pressure from the Trump administration to lower costs. According to exclusive data from healthcare research firm 3 Axis Advisors, the number of price increases for 2026 has surged compared to last year, with a median list price hike of 4%—mirroring 2025 trends. And this is the part most people miss: even companies that struck pricing deals with the Trump administration are among those raising prices.
The Bigger Picture: Why Are Prices Still Climbing?
While drugmakers are quick to point to inflation and the need for innovation, critics argue that these increases are excessive, especially when U.S. patients already pay nearly three times more for prescription medicines than those in other developed nations. For instance, Pfizer—one of the companies raising prices—announced hikes on around 80 drugs, including a 15% increase for its COVID vaccine Comirnaty. The company claims these adjustments are below the overall inflation rate, but is that enough? What do you think? Are these price hikes justified, or is this another example of corporate greed?
The Other Side of the Coin: Some Prices Are Dropping
It’s not all bad news. Drugmakers are also cutting prices on a handful of medications, most notably Boehringer Ingelheim’s diabetes drug Jardiance, which is seeing a staggering 40% reduction. This comes after the U.S. government negotiated lower prices for Medicare, slashing Jardiance’s cost by two-thirds. But here’s the catch: these cuts are the exception, not the rule. And this is the part most people miss: even with these reductions, the overall trend is still upward, leaving many to wonder if these gestures are merely symbolic.
Behind the Scenes: The Complex World of Drug Pricing
Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital, points out that these deals often “nibble around the margins” without addressing the root causes of high drug prices. He argues that companies are maximizing profits by negotiating discounts with insurers while maintaining high list prices for cash-paying consumers. Is this a fair system, or does it exploit those who can least afford it?
What’s Next? The January Price Surge
Historically, January is the biggest month for drug price increases, so expect more announcements soon. Companies like GSK, Sanofi, and Novartis are all planning hikes, citing the need to fund scientific innovation. But with U.S. patients already bearing the brunt of skyrocketing costs, the question remains: how much is too much? We want to hear from you: Are drugmakers prioritizing profits over people, or is this the cost of medical progress?
As the debate rages on, one thing is clear: the battle over drug prices is far from over. Stay tuned for more updates, and don’t forget to share your thoughts in the comments below!
